Iteris, Inc. (NASDAQ:ITI) shares moved down -0.42% in last trading session and ended the day at $2.39. ITI Gross Margin is 39.40% and its has a return on assets of -17.60%. Iteris, Inc. (NASDAQ:ITI) quarterly performance is 3.46%.
Iteris, Inc. (NASDAQ:ITI) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,MarketBeat.Com reports.
NCI, Inc. (NASDAQ:NCIT) ended the last trading day at $13.74. Company weekly volatility is calculated as 3.75% and price to cash ratio as 928.82. NCI, Inc. (NASDAQ:NCIT) showed a weekly performance of -1.51%.
NCI, Inc. (NASDAQ:NCIT) announced it was awarded a five-year, multiple-award blanket purchase agreement (BPA) with a ceiling value of $25 million through the General Services Administration (GSA) and its 18F technology consulting group to provide agile services. The award is subject to the terms and conditions of the company’s GSA Schedule 70. GSA’s Assisted Acquisition Services office will manage the post-award task orders.
On 08 April, LDR Holding Corporation (NASDAQ:LDRH) shares moved down -0.87% and was closed at $26.28. LDR Holding Corporation (NASDAQ:LDRH) year to date (YTD) performance is 4.66%.
On 29 March, LDR Holding Corporation (NASDAQ:LDRH) announced that “Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of two-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial” has been published by the Journal of Neurosurgery: Spine. Mobi-C provided statistically significant greater improvement in general and disease specific outcome measures compared to Anterior Cervical Discectomy and Fusion (ACDF).
MannKind Corp. (NASDAQ:MNKD) shares moved down -10.95% in last trading session and ended the day at $1.22. MNKD has a return on assets of -131.90%. MannKind Corp. (NASDAQ:MNKD) quarterly performance is 76.56%.
MannKind Corp. (NASDAQ:MNKD) announced that it has withdrawn its offer to employ Duane M. DeSisto as its President and Chief Executive Officer as a consequence of objections raised by Insulet Corp., the former employer of DeSisto, that the employment of DeSisto by MannKind would violate Insulet’s non-competition agreement with DeSisto, which is in effect until Sept. 17, 2016.
Enzymotec Ltd. (NASDAQ:ENZY) caters to the Healthcare space. It has a net profit margin of 13.30% and weekly performance is 2.92%. On the last day of trading company shares ended up at $8.80. Enzymotec Ltd. (NASDAQ:ENZY) distance from 50-day simple moving average (SMA50) is -0.06%.
On 29 March, Enzymotec Ltd. (NASDAQ:ENZY) announced that the Company has been granted two patents, one by the United States Patent Office and the second by the Chinese Patent and Trademark Office.